

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
11 May 2023 (11.05.2023)



(10) International Publication Number
WO 2023/081896 A1

(51) International Patent Classification:

C12N 5/078 (2010.01) C07K 14/735 (2006.01)
C12N 5/074 (2010.01) C07K 14/54 (2006.01)
C07K 14/715 (2006.01) A61P 37/02 (2006.01)
C07K 14/725 (2006.01) A61P 35/00 (2006.01)

SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(21) International Application Number:

PCT/US2022/079412

(22) International Filing Date:

07 November 2022 (07.11.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/277,034 08 November 2021 (08.11.2021) US
63/329,203 08 April 2022 (08.04.2022) US

(71) Applicant: **FATE THERAPEUTICS, INC.** [US/US];
12278 Scripps Summit Drive, San Diego, CA 92131 (US).

(72) Inventors: **HOSKING, Martin**; 12278 Scripps Summit Drive, San Diego, CA 92131 (US). **VALAMEHR, Bahram**; 12278 Scripps Summit Drive, San Diego, CA 92131 (US). **SHIRINBAK, Soheila**; 12278 Scripps Summit Drive, San Diego, CA 92131 (US).

(74) Agent: **GIERING, Jeffery, C.** et al.; Greenberg Traurig, LLP, 18565 Jamboree Road, Suite 500, Irvine, CA 92612 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI,

(54) Title: ENGINEERED EFFECTOR CELLS FOR TRAFFICKING OF ALLOGENEIC CELL THERAPIES IN SOLID TUMORS

(57) Abstract: Provided are methods and compositions including for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. Also provided are derivative cells having stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.

WO 2023/081896 A1